Activation of cAMP signalling via means other than by activating GNAS mutations suggests both an explanation for off-label drugs with potential actions against cancer, and the means to identify additional cancer targeting drugs (Table 1, Table S19; Fig. S13). The gene discussed is GNAS; the disease is cancer.